drugset / Trial / NCT05856227

Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age

NCT05856227

Phase 3 Completed 9 enrolled Basilea Pharmaceutica
NaSingle-groupOpen-labelTreatment

Summary

This study evaluated the safety, pharmacokinetics and efficacy of ceftobiprole in term and pre-term newborn babies and infants up to 3 months of age with late-onset sepsis (LOS). Ceftobiprole is an antibiotic which belongs to a group of medicines called 'cephalosporin antibiotics'. It is approved for its use to treat adults and children with pneumonia in many European and non-European countries.

Timeline

Start
2023-08-06
Primary completion
2024-12-18
Completion
2024-12-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Ceftobiprole Small molecule 7.5 mg/kg Intravenous
Subject Ceftobiprole Small molecule 15 mg/kg Intravenous

Indications